Literature DB >> 19380869

CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling.

Angélique Levoye1, Karl Balabanian, Françoise Baleux, Françoise Bachelerie, Bernard Lagane.   

Abstract

The stromal cell-derived factor-1/CXCL12 chemokine engages the CXCR4 and CXCR7 receptors and regulates homeostatic and pathologic processes, including organogenesis, leukocyte homeostasis, and tumorigenesis. Both receptors are widely expressed in mammalian cells, but how they cooperate to respond to CXCL12 is not well understood. Here, we show that CXCR7 per se does not trigger G(alphai) protein-dependent signaling, although energy transfer assays indicate that it constitutively interacts with G(alphai) proteins and undergoes CXCL12-mediated conformational changes. Moreover, when CXCR4 and CXCR7 are coexpressed, we show that receptor heterodimers form as efficiently as receptor homodimers, thus opening the possibility that CXCR4/CXCR7 heterodimer formation has consequences on CXCL12-mediated signals. Indeed, expression of CXCR7 induces conformational rearrangements within preassembled CXCR4/G(alphai) protein complexes and impairs CXCR4-promoted G(alphai)-protein activation and calcium responses. Varying CXCR7 expression levels and blocking CXCL12/CXCR7 interactions in primary T cells suggest that CXCR4/CXCR7 heterodimers form in primary lymphocytes and regulate CXCL12-promoted chemotaxis. Taken together, these results identify CXCR4/CXCR7 heterodimers as distinct functional units with novel properties, which can contribute to the functional plasticity of CXCL12.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19380869     DOI: 10.1182/blood-2008-12-196618

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  257 in total

1.  Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists.

Authors:  Beili Wu; Ellen Y T Chien; Clifford D Mol; Gustavo Fenalti; Wei Liu; Vsevolod Katritch; Ruben Abagyan; Alexei Brooun; Peter Wells; F Christopher Bi; Damon J Hamel; Peter Kuhn; Tracy M Handel; Vadim Cherezov; Raymond C Stevens
Journal:  Science       Date:  2010-10-07       Impact factor: 47.728

Review 2.  CXCL12 in control of neuroinflammation.

Authors:  Miljana Momcilović; Marija Mostarica-Stojković; Djordje Miljković
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

3.  CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells.

Authors:  Sven Jähnichen; Christophe Blanchetot; David Maussang; Maria Gonzalez-Pajuelo; Ken Y Chow; Leontien Bosch; Sindi De Vrieze; Benedikte Serruys; Hans Ulrichts; Wesly Vandevelde; Michael Saunders; Hans J De Haard; Dominique Schols; Rob Leurs; Peter Vanlandschoot; Theo Verrips; Martine J Smit
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-08       Impact factor: 11.205

4.  The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains.

Authors:  Stéphanie Gravel; Camille Malouf; Philip E Boulais; Yamina A Berchiche; Shinya Oishi; Nobutaka Fujii; Richard Leduc; Daniel Sinnett; Nikolaus Heveker
Journal:  J Biol Chem       Date:  2010-10-18       Impact factor: 5.157

5.  Carboxy-terminus of CXCR7 regulates receptor localization and function.

Authors:  Paramita Ray; Laura Anne Mihalko; Nathaniel L Coggins; Pranav Moudgil; Anna Ehrlich; Kathryn E Luker; Gary D Luker
Journal:  Int J Biochem Cell Biol       Date:  2012-01-25       Impact factor: 5.085

6.  CXCL12-CXCR4/CXCR7 axis contributes to cell motilities of oral squamous cell carcinoma.

Authors:  Na Chen; Xiao Jiang; Juan Wang; Tong Wu; Bin Cheng; Juan Xia
Journal:  Tumour Biol       Date:  2015-08-02

7.  Dual targeting of the chemokine receptors CXCR4 and ACKR3 with novel engineered chemokines.

Authors:  Melinda S Hanes; Catherina L Salanga; Arnab B Chowdry; Iain Comerford; Shaun R McColl; Irina Kufareva; Tracy M Handel
Journal:  J Biol Chem       Date:  2015-07-27       Impact factor: 5.157

Review 8.  Endocytic trafficking of chemokine receptors.

Authors:  Adriano Marchese
Journal:  Curr Opin Cell Biol       Date:  2013-12-14       Impact factor: 8.382

9.  CXCL12 Retargeting of an Oncolytic Adenovirus Vector to the Chemokine CXCR4 and CXCR7 Receptors in Breast Cancer.

Authors:  Samia M O'Bryan; J Michael Mathis
Journal:  J Cancer Ther       Date:  2021-06

10.  A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators.

Authors:  Sandra Claes; Thomas D'huys; Anneleen Van Hout; Dominique Schols; Tom Van Loy
Journal:  J Vis Exp       Date:  2018-02-20       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.